This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Although CLIA specifies minimum retention periods, it does not explicitly state which entity retains ownership of the specimen during retention and after the retention period. The US currently lacks well-defined federal regulations governing the ownership and use of physical human tissue specimens, their derivatives, and the biological information they contain. The current standing by bioethicists is that patients who have consented to have their diagnostic specimens collected have also abandoned them, and thus have no ownership rights. The Common Rule permits the use of biospecimens that would otherwise be discarded, provided that the donor can not be identified, though utilization of the materials for research may require Institutional review board (IRB) approval. The Association of American Medical Colleges (AAMC) has taken the stance that it "unambiguously rejects the concept that individuals retain any property interest in their excised tissues." Proponents of patient ownership rights advocate that patients must own their samples so that they can make informed decisions about how the tissues will be used, such as in bioweapons development, stem cell research, and for-profit ventures.
== External links == Media related to Scutellaria at Wikimedia Commons Data related to Scutellaria at Wikispecies "Scutellaria L. (skullcap)". The PLANTS Database. United States Department of Agriculture. Scutellaria images. MorphBank.
Natural killer cell (NK) therapies and CAR-NK cell approaches are also being explored, leveraging NK cells' innate ability to target tumor cells. Other strategies include cancer vaccines, which aim to provoke an immune response against tumor-associated antigens, and may be either preventive or therapeutic. Immunomodulatory agents such as cytokines (e.g., interleukin-2, interferon-alpha) and Bacillus Calmette-Guerin (BCG) are used to enhance immune activity or alter the tumor microenvironment. Oncolytic virus therapies, which employ engineered viruses to selectively kill cancer cells while promoting systemic immunity, are also under investigation. In 2018, American immunologist James P. Allison and Japanese immunologist Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation.
Naphthalene, an organic compound commonly found in pesticides such as mothballs, sublimes easily because it is made of non-polar molecules that are held together only by van der Waals intermolecular forces. Naphthalene is a solid that sublimes gradually at standard temperature and pressure, at a high rate, with the critical sublimation point at around 80 °C. At low temperature, its vapour pressure is high enough, 1 mmHg at 53 °C, to make the solid form of naphthalene evaporate into gas. On cool surfaces, the naphthalene vapours will solidify to form needle-like crystals.
Today, each region in Japan has its own brand of Wagyu beef, numbering more than 320. The first Wagyu beef to gain a reputation was Kobe beef, already famous since the 1860s and known to foreign countries through foreign residents. Ōmi beef also had a reputation since the Meiji era (1868–1912) for its delicious taste. In the Taisho era (1912–1926), Matsusaka beef also became well known. These were originally Tajima cattle, and calves were purchased from the Tajima region, fattened in each region, and then sold. In the Tokyo area, Yonezawa beef has also been known since the Meiji era. Since the 1980s, Wagyu beef branding has been promoted in various regions of Japan. However, the Japanese Trademark Law at the time did not allow for the establishment of regional collective trademarks, which posed a problem in terms of legal protection. Before the Beef Traceability Law (2003) was enacted, there were also issues regarding the verification of the origin, breeding location, and distribution of Wagyu beef. In 2006, the Japanese Trademark Law was amended to recognize regional collective trademarks, allowing Wagyu beef to be registered as a "regional brand." In 2014, the Geographical Indications Law was passed, and the operation of Geographical Indications (GI) protection began in 2015. Currently, the GI-registered brands of Wagyu beef are as follows.
Sources: en.wikipedia.org
If insufficient quantities of copper are ingested, copper reserves in the liver will become depleted and a copper deficiency leading to disease or tissue injury (and in extreme cases, death). Toxicity from copper deficiency can be treated with a balanced diet or supplementation under the supervision of a doctor. On the contrary, like all substances, excess copper intake at levels far above World Health Organization limits can become toxic. Acute copper toxicity is generally associated with accidental ingestion. These symptoms abate when the high copper food source is no longer ingested. In 1996, the International Program on Chemical Safety, a World Health Organization-associated agency, stated "there is greater risk of health effects from deficiency of copper intake than from excess copper intake". This conclusion was confirmed in recent multi-route exposure surveys. The health conditions of non-genetic copper deficiency and copper excess are described below.
On 14 August 1926, Oscar Tiegs married Ethel Mary Hamilton, a telephonist, at the Presbyterian Church in the Melbourne suburb of Hawthorn. Tiegs was known to form lasting friendships, even from relatively brief associations. For example, colleagues he met only once while on a trip to Europe in 1928, had fond memories of him. He was known as Sandy Tiegs to his friends and colleagues. He was godfather to David, the son of his mentor and colleague, Professor Brailsford Robertson. Tiegs was always interested in learning and research, and was known to find administration and committee work distasteful. This would appear to be at odds with his being a Councillor, and Chair of the Library Committee, for The Royal Society of Victoria. As head of the Melbourne University's Department of Zoology, he encouraged research and empowered his staff to set their own courses of activity with a directed freedom that nurtured world class research. He tended not to be interested in the research of others unless it was closely aligned with his own, yet was proud of his staff and was keen to show visitors what his staff were doing. He lectured without notes, mainly to first year students, to whom he gave a solid background in elementary zoology and comparative morphology, in a manner which was considered a model of presentation and clarity. He gave special lectures on arthropod evolution and the vertebrate nervous system to senior students.
One study of an elderly Japanese population found correlations between the MTHFR 677CT mutation, an Apo E polymorphism, and certain types of senile dementia. Other research has found that individuals with folate-related mutations can still have a functional deficiency even when blood levels of folate are within the normal range, and recommended supplementation of methyltetrahydrofolate to potentially prevent and treat dementia (along with depression). A 2011 study from China also found that the C677T SNP was associated with Alzheimer's disease in Asian populations (though not in Caucasians). C677T polymorphism is associated with risk of myocardial infarction in African, North American, and elderly populations. The CDC provides a web page with information on the "MTHFR Gene, Folic Acid, and Preventing Neural Tube Defects". National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. 27 May 2025. Retrieved 6 Jun 2025.
Molecular analysis of CPOX is the best way to identify these patients, as they will not express a biochemical phenotype on laboratory testing unless they are symptomatic. Identification of asymptomatic patients allows them to adjust their lifestyle to avoid common triggering factors.
guanosine (G, Guo) One of the four standard nucleosides used in RNA molecules, consisting of a guanine base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. Guanine bonded to deoxyribose is known as deoxyguanosine, which is the version used in DNA.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.